Fig. 1: Increased RSUME expression is correlated with VHL missense mutations and poor survival in RCC patients.

a Representative immunohistochemistry (IHC) staining for RSUME in three ccRCC patient samples. Scale bars 100 µm and 50 µm as indicated. b Kaplan–Meier analysis in patients stratified as having high (violet line) RSUME expression or low (blue line) RSUME expression (expression cutoff 2.9 FPKM), publically available from The Human Protein Atlas. c Box plots comparison between RSUME mRNA expression in a patient stratification of the Additional file 8: Table S1 data (where VHLwt = 207 samples without mutations in VHL gene, VHLmut = 245 samples with mutations in VHL gene). *Significant differences between sample groups distribution with a P = 0.048, < 0.05 (Mann–Whitney U-test). d Box plots comparison between RSUME mRNA expression in a patient stratification of the Additional file 8: Table S1 data with mutations in VHL cohort (VHLmut) into tumor stages (where stage I–II represent samples corresponding to tumor stages I and II = 150 samples; stage III represents samples corresponding to tumor stage III = 58 samples; stage IV represents samples corresponding to tumor stage IV = 37 samples). Significant differences between sample group means with a P = 0.036 (_*) and 0.021 (#), < 0.05 (ANOVA and post hoc Tukey tests). e, f Box plots comparison between RSUME mRNA expression in a patient stratification of the Additional file 8: Table S1 data in stage IV cohort into mutation types (where VHLwt = 34 samples without mutations in VHL gene, VHLmut = 37 samples with mutations in VHL gene, VHLmiss = 18 samples with mutations missense in VHL gene only). *Significant differences between sample groups distribution with a P = 0.012 (5e), and 0.027 (5f), < 0.05 (Mann–Whitney U-test)